Etanercept biosimilar - mAbxience
Alternative Names: mAbx01Latest Information Update: 18 Apr 2023
Price :
$50 *
At a glance
- Originator mAbxience
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 24 Mar 2023 Discontinued - Preclinical for Autoimmune disorders in Switzerland (Parenteral) (mAbxience pipeline, March 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland (Parenteral)
- 02 Aug 2016 Preclinical development is ongoing